The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $64
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Intellia Therapeutics Is Maintained at Buy by Stifel
Express News | Intellia Therapeutics Inc : Stifel Cuts Target Price to $64 From $80
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Latest 6.7% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant
OhNowGombie : Another quack you mean? Totally out of her gourd too